Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: A randomized, double-blind, placebo-controlled study with an open-label extension

Annals of Allergy, Asthma and Immunology

Volumn 102, Issue 4, 2009, Pages 339-347

  Weinstein, Steven ^a   Qaqundah, Paul ^b   Georges, George ^c   Nayak, Anjuli ^d  

^a Research Center   (United States)

^b Pediatric Medical Care Group Inc   (United States)

^c Sanofi aventis US Inc   (United States)

^d Sneeze Wheeze and Itch Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; NOSE SPRAY; PLACEBO; TETRACOSACTIDE; TRIAMCINOLONE ACETONIDE;

ABRASION; ARTICLE; ASTHMA; BODY HEIGHT; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; EAR INFECTION; EPISTAXIS; EXCORIATION; FEMALE; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OTITIS MEDIA; PERENNIAL RHINITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SINUSITIS; SORE THROAT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING;

EID: 65249162814     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60340-7     Document Type: Article

References (34)

1. Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics. 1994;94:895-901.
2. Gelfand EW. Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J. 2005;84:163-168.
3. Gentile D, Shapiro G, Skoner D. Allergic Rhinitis. St Louis, MO: Mosby; 2003.
4. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63:8-160.
5. Schmidt LJ, Garratt AM, Fitzpatrick R. Child/parent-assessed population health outcome measures: a structured review. Child Care Health Dev. 2002;28:227-237.
6. Bukstein DA, McGrath MM, Buchner DA, Landgraf J, Goss TF. Evaluation of a short form for measuring health-related quality of life among pediatric asthma patients. J Allergy Clin Immunol. 2000;105:245-251.
7. Brouwer CN, Schilder AG, van Stel HF, et al. Reliability and validity of functional health status and health-related quality of life questionnaires in children with recurrent acute otitis media. Qual Life Res. 2007;16: 1357-1373.
8. Dluhy RG. Clinical relevance of inhaled corticosteroids and HPA axis suppression. J Allergy Clin Immunol. 1998;101:S447-S450.
9. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105:E23.
10. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once- daily mometasone furoate aqueous nasal spray in children. Clin Ther. 1997;19:1330 -1339.
11. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92:594-599.
12. Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr. 1994;125:628-634.
13. Boner A, Sette L, Martinati L, Sharma RK, Richards DH. The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis. Allergy. 1995;50:498-505.
14. Richards DH, Milton CM. Fluticasone propionate aqueous nasal spray: a well-tolerated and effective treatment for children with perennial rhinitis. Pediatr Allergy Immunol. 1996;7:35-43.
15. Maspero JF, Rosenblut A, Finn A Jr, Lim J, Wu W, Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg. 2008;138:30-37.
16. Fokkens WJ, Scadding GK. Perennial rhinitis in the under 4s: a difficult problem to treat safely and effectively? a comparison of intranasal fluticasone propionate and ketotifen in the treatment of 2-4-year-old children with perennial rhinitis. Pediatr Allergy Immunol. 2004;15:261-266.
17. Pediatric Research Equity Act of 2003. http://frwebgate.access.gpo.gov/ cgi-bin/getdoc.cgi?dbname=108-cong-public-laws&docid=f:publ155. 108.
18. PREA Working Group at the Food and Drug Administration (FDA). Guidance for industry: how to comply with the Pediatric Research Equity Act: draft guidance, August 30, 2005. Biotechnol Law Rep. December 1, 2005;24:759 -770. doi:10.1089/blr.2005.24.759.
19. Nasacort AQ prescribing information. http://products.sanofi-aventis.us/ Nasacort-AQ/nasacort-aq.pdf.
20. Munk ZM, LaForce C, Furst JA, Simpson B, Feiss G, Smith JA. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1996;77:277-281.
21. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90:56-62.
22. Ober S, Gentile D, Kairis E, Barnoski K, Doyle W, Skoner DP. Growth velocity and HPA axis function during 1-yr treatment with triamcinolone acetonide aqueous (TAA) nasal spray in children with allergic rhinitis (AR). J Allergy Clin Immunol. 2005;115:267.
23. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol. 1998;101:157-162.
24. Kaiser HB, Liao Y, Diener P, Leahy MJ, Garcia J, Georges G. Triam- cinolone acetonide and fluticasone propionate nasal sprays provide comparable relief of seasonal allergic rhinitis symptoms regardless of disease severity. Allergy Asthma Proc. 2004;25:423-428.
25. Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg. 2003;129:16-23.
26. Gross G, Jacobs RL, Woodworth TH, Georges GC, Lim JC. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2002;89:56-62.
27. Skoner DP, Gentile DA, Doyle WJ. Effect on growth of long-term treatment with intranasal triamcinolone acetonide aqueous in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2008;101:431-436.
28. Nayak A, Berger W, Liao Y, Garcia J, Georges G; Study 4007 Investigator Group. Tolerability and treatment response at starting dose of triamcinolone acetonide AQ and budesonide AQ in patients with seasonal allergic rhinitis [abstract]. Allergy Asthma Proc. 2005;26:233.
29. Schmidt IL, Lahner H, Mann K, Petersen S. Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab. 2003;88:4193-4198.
30. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003;139:194-204.
31. National Center for Health Statistics. 2000 CDC growth charts. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/ growthcharts.
32. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. Rockville, MD: Center for Drug Evaluation and Research; April 2003.
33. Tordjman K, Jaffe A, Trostanetsky Y, Greenman Y, Limor R, Stern N. Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol (Oxf). 2000;52:633-640.
34. Bernstein DI, Allen DB. Evaluation of tests of hypothalamic-pituitary- adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2007;98:118 -127.